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Introduction
Hospi talizations are common for patients with diabetes, 1-2 and since 1988, the number of patients discharged from the hospital with a diagnosis of diabetes has doubled. 3 Moreover, hospitalizations represent the largest share of economic costs associated with diabetes. 4 Recent data have indicated that good blood glucose control in hospitalized patients may result in better outcomes. [5] [6] Quality improvement organizations are developing standards for inpatient diabetes management [7] [8] and are working to disseminate guidelines for inpatient diabetes care. 9 Continuous subcutaneous insulin infusion (CSII), commonly referred to as the insulin pump, delivers intensive insulin therapy to optimize glucose control. As the popularity of CSII increases, hospital health care providers may more frequently face the issue of how to manage the inpatient care of patients who have been receiving outpatient insulin pump therapy. Many of these patients have invested considerable time and money in an attempt to master the technology. Our clinical experience has indicated that patients receiving CSII would like to continue their therapy in the hospital, but at the same time may be uncomfortable in transferring responsibility and control of diabetes care to hospital staff.
We recently designed and published guidelines to assist practitioners with the management of CSII in our hospital. 10 The guidelines were developed both as a result of an institutional gap in care of the hospitalized patient with an insulin pump, and as a response to the very limited availability of peer reviewed published suggestions on how to manage care of a patient with CSII when he or she has been admitted to the hospital.
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The objectives of our inpatient guidelines were to promote the patient's independence in the use of the insulin pump during hospitalization while maximizing the patient's safety in accordance with established requirements for glucose self-management. 12 We present a review of how the inpatient insulin pump policy has performed and show data on the quality of glycemic control in patients who received insulin pump therapy throughout their hospital stay.
Methods

Description of Facility
Our tertiary care academic teaching hospital is a 200-bed facility in metropolitan Phoenix, Arizona. All general medical and surgical specialties for adult patients are that the patient received CSII therapy before admission were recorded. We also determined staff compliance with major policy components (documentation by nursing of the presence of the pump at the time of admission; measurement of an admission glucose; presence of a signed patient consent form; evidence of completed preprinted insulin pump orders; an endocrine consultation; documentation of a completed bedside flow sheet).
To assess the status of glucose control among patients remaining on CSII therapy, we averaged bedside glucose measurements for each patient and determined the composite bedside glucose average (BedGlucavg) level.
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We calculated the frequency of hypoglycemic values (bedside glucose <70, <60, <50, and <40 mg/dl) and hyperglycemic values (bedside glucose >200, >250, >300, >350, and >400 mg/dl) for each patient, and we reported the results as the quantity of these values per patient per 100 measurements. This method allowed adjustment for different numbers of measurements across the patients and captured information on multiple episodes of hypoglycemia or hyperglycemia in individual patients.
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Results
Patient Characteristics
Between November 1, 2005, and November 30, 2006, there were 25 hospital admissions involving 21 unique patients receiving insulin pump therapy; one patient was hospitalized on four separate occasions and another had two admissions. Of the 21 patients, 7 were not being managed as outpatients by our endocrinology staff before admission. The mean age of the 21 patients was 50 years, with an average duration of diabetes of 29 years. The average duration of CSII therapy was four years and the average length of stay was four days. All patients were white, 67% were women, and 90% were identified in their records as having type 1 diabetes ( Table 3) ; one patient did not have documentation of diabetes type. Most of the patients were admitted for an acute problem (e.g., emesis, fever, positive stress test requiring urgent coronary artery bypass grafting). Three hospitalizations involved elective short-stay procedures (e.g., lymph node removal, dilatation and curettage, renal stone lithotripsy).
Continuous subcutaneous insulin infusion therapy was discontinued in 9 of the hospitalizations and continued in 16. Reasons for discontinuation included the patient not having access to his or her insulin pump supplies, altered mental status, receipt of a pancreas transplant, and pump malfunction. Two admissions involved patients who required a major operative procedure (e.g., coronary
Operationally, hospital CSII procedures require a signed patient consent and completion of a template of orders and a bedside flow sheet. The consent form (Appendix 2) instructs the patient to provide their own insulin pump supplies (e.g., infusion sets, catheters), because it is not practical for our facility to stock these items. The order set (Appendix 3) guides the practitioner principally on how to order insulin pump basal rates and bolus amounts, and includes a requirement for an endocrinology consultation. The bedside flow sheet (Appendix 4) is used by the patient to record basal rates, bolus amounts, carbohydrate intake, and bedside glucose values.
In our original publication of the policy, we proposed metrics to characterize hospitalized patients receiving insulin pump therapy and to evaluate their outcomes. These metrics included age, sex, duration of diabetes, length of stay, pump-related adverse events, proportion of consent forms signed by the patient, use of the preprinted order sets and bedside flow sheets, and data on glucose control.
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Case Selection
From November 1, 2005, to November 30, 2006, we recorded 25 hospital admissions involving a patient with an insulin pump. We conducted a retrospective chart review to determine whether the CSII policy had been implemented in these cases. The initial nursing assessment was recorded electronically; other documents (consent form, flow sheet, and order set) were scanned into the electronic medical record.
Extraction of Glucose Data
After we identified hospital cases involving an insulin pump, we linked data through identifiers of patients to our electronic laboratory database to retrieve information on capillary glucose values. In our institution, bedside glucose monitoring is performed with an instrument that scans and records patient identification, followed by direct downloading to our laboratory database. Commercial software (Medical Automation Systems, Inc., Charlottesville, Virginia) facilitates the interface of glucometer data with the electronic laboratory file.
Data Analysis
We used our proposed metrics as a template to review the performance of our inpatient insulin pump therapy. Basic demographics (age, sex, race/ethnicity, reason for admission, and length of hospital stay) were extracted from the electronic medical record. Available data on type of diabetes, duration of diabetes, and length of time artery bypass grafting); in these instances, the insulin pump therapy was discontinued during the procedure but restarted after recovery. If CSII therapy was temporarily discontinued for a surgical procedure and restarted and then maintained after recovery from the procedure, we considered these cases as having continued CSII therapy during the hospital stay. CSII therapy was discontinued in one patient who had congenital deafness; on further evaluation of the patient's knowledge about diabetes, we discovered that she did not understand how to adjust her pump settings, and she began receiving subcutaneous insulin injections.
Adherence to Post-Admission Procedures
The presence of an insulin pump was documented at hospitalization in 84% of all 25 CSII-related admissions, the brand of the pump in 68%, and the type of insulin being infused in 80%. Because some patients had the insulin pump discontinued appropriately after their initial assessment, we examined compliance with the policy for only the 16 hospitalizations in which CSII therapy was continued. In these 16 hospital cases, review of the initial nursing assessment showed that 81% of patients had the presence of the insulin pump recorded, 69% the brand of the pump, and 81% the type of insulin being infused ( Table 4 ). All hospital admissions were accompanied by an assessment of glucose level. Written consent was included in the documentation of 88% of patients who continued the insulin pump therapy and the completed preprinted order set was found in the documentation of 81%. An endocrinology consultation was requested in 75% of cases in which the pump therapy was continued; the bedside flow sheet was found in 75%. No adverse events were reported in the patients who continued insulin pump therapy.
Glycemic Control
Among the 16 hospitalizations in which CSII therapy was continued, the mean length of hospital stay was 4 days (range, 1-25 days); however, 50% of the patients were hospitalized for only 1 day. The average number of bedside glucose values was 4.5 per day (range, 1-6). The mean blood glucose level at admission was 189 mg/dl and the mean level at discharge was 166 mg/dl. Overall, glucose control was fair in these 16 hospitalizations, with a mean BedGlucavg of 187 mg/dl. Hypoglycemia occurrences were less common than hyperglycemia incidents: 33% of patients had at least one bedside glucose value that was less than 70 mg/dl, but 80% had at least one value that was greater than 200 mg/dl. The frequency of hypoglycemic measurements was lower ( Figure 1A ) than the frequency of hyperglycemic measurements ( Figure 1B) . A question does arise about how effective CSII is in managing inpatient hyperglycemia. The frequencies of hypoglycemic and hyperglycemic events in these patients who used an insulin pump were higher than in our general population of non-critically ill hospitalized patients with diabetes, 15 Data from our hospital [15] [16] indicate that among non-critically ill hospitalized patients with diabetes, the prevalence of hypoglycemia (bedside glucose, <70 mg/dl) was only 21% and averaged about 2 episodes per patient per 100 bedside glucose measurements. Among the patients remaining on CSII who were evaluated here, however, hypoglycemia was far more frequent, with a prevalence of 33% and a frequency of nearly 6 episodes per patient per 100 measurements. In addition, hyperglycemia was more common among CSII-treated patients. In our population of non-critically ill patients with diabetes, 68% had hyperglycemia (bedside glucose, >200 mg/dl) with a frequency of about 25 episodes per patient per 100 measurements. 15 However, 80% of the patients remaining on insulin pump therapy had hyperglycemia, with a frequency that averaged almost 40 episodes per patient per 100 measurements.
Although our data suggest that CSII may not be effective in treating inpatient hyperglycemia, no definitive conclusion can be made yet about the ability of insulin pumps to manage hyperglycemia adequately in hospitalized patients. Our number of available insulinpump cases was too small to assess the efficacy of CSII in controlling glucose levels in the acute-care setting. Moreover, a large percentage of the patients who used an insulin pump were hospitalized for only a single day, which makes it difficult to introduce any changes in insulin delivery rates or to evaluate the effect of such changes. The type of diabetes (type 1 vs type 2), the duration of diabetes, and the severity of diabetes complications may all factor into how effective CSII can be in controlling hyperglycemia in the hospital. Over time, our sample size will undoubtedly increase, and as it does, better evaluation of the efficacy of CSII in the hospital setting can be conducted.
A limitation of our analysis is that we cannot be certain that we identified every patient receiving insulin pump therapy who was admitted to our hospital. We now have the capability to produce a daily electronic report identifying patients with an insulin pump who are admitted. This report is made possible because CSII infusion rates are entered electronically into the pharmacy database. This capability allows us to conduct a daily electronic survey of new patients with insulin pumps and to alert the inpatient endocrinology team to conduct assessments.
Discussion
The experience at our institution has been that patients who receive CSII as outpatients are eager to continue the therapy during a hospital stay. However, insulin errors are common in the hospital setting.
17-20 Also, insulin pumps are foreign to most hospital personnel and add to the already complicated nature of the delivery of insulin therapy. Because of the differences in the available insulin pump models and the infrequency of seeing patients who use an insulin pump, practitioners in hospitals cannot be expected to become experts on the assessment and management of CSII. Thus, the potential for errors in CSII use is likely great. However, patients who receive insulin pump therapy are educated intensively in diabetes selfmanagement and invest considerable time in mastering insulin pump technology and could be allowed to selfmanage under the right circumstances. With the dual goals of allowing patients the flexibility to continue their insulin pump therapy while ensuring their safety, we developed a policy to guide personnel and patients on the continued use of CSII in the hospital. 10 This analysis is a follow-up to that first published report and was conducted to determine how well the guidelines were implemented.
Nearly two-thirds of hospitalized patients were able to continue or restart CSII therapy following admission. We found that overall institutional compliance with the insulin pump policy was high: the presence of the pump was documented at the time of hospital admission, and among patients who continued on CSII therapy during the hospital stay, the consent form was signed, a glucose level reading was taken, the bedside flow sheet and order set were completed, and the necessary consultations were requested in most cases. In some instances, the required elements were missing; however, we were unable to determine whether items were missing because staff did not comply with necessary procedures or the components simply were not scanned into the medical record. We have conducted extensive and ongoing education for staff, including nurses, midlevel health care professionals (i.e., nurse practitioners and physician assistants), and resident physicians, about the use of inpatient insulin pumps; however, familiarization with the policy may not yet be widespread within the institution and, hence, some nonadherence would have been expected as the insulin pump policy was introduced.
Emerging evidence indicates that hyperglycemia in hospitalized patients leads to worse outcomes and that blood glucose control improves those outcomes.
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Another limitation of this study is the difficulty in calculating from available data the amount of insulin delivered by the pump. One of our original metrics was to calculate daily amounts of insulin and track basal infusion rates. 10 We previously extracted non-insulin pump data from our electronic records. 15 Although the presence of the insulin pump is documented in these records and the basal and bolus rates are recorded on the bedside flow sheet, the determination of the total daily insulin doses from this format is cumbersome and we found that the pump basal rates/bolus amounts may not be a practical (or even important) metric to track.
One of the new challenges we face in the continued implementation of our inpatient insulin pump policy is our upcoming transition to computerized physician order entry (CPOE). CPOE has required migration of the preprinted insulin pump order set from a paper format to an electronic one. Future training will require familiarization of staff not only with the principles of the insulin pump procedures but also with how to order using the CPOE system. In addition, some questions have arisen about the operation of CSII intraoperatively-an issue our original policy did not address.
We believe that, in general, implementation of our inpatient insulin pump policy has been successful. Patients are identified at admission and assessed for their candidacy for continued CSII use, and the pump therapy is discontinued if it is not deemed appropriate. Patient consent is obtained, and necessary documentation is achieved for most patients, although improvement is needed to reach 100% compliance in performance of all components. Our analysis also provided us with new information about the characteristics of the inpatient population that receives CSII. Furthermore, no adverse events have been associated with the use of CSII in properly selected patients, and patients have been accepting of the necessary requirements for selfmanagement. Determining whether CSII is an effective means to control hyperglycemia in the hospital setting will require ongoing investigation. 
DRAFT
A physician order is written as necessary for: leaving the pump in place and continuing the basal rate; the frequency of blood glucose monitoring; bolus algorithms for meals and hyperglycemia; the basal rate or changes to the basal rate; the target glucose range; the patient/family to assist in site and rate changes.; removal of the insulin pump prior to any radiological procedure.
The registered nurse (RN) and/or physician assess the patient's level of consciousness including person, place, time, and appropriateness to situation.
If the patient is alert and appropriate, the patient continues to use the CSII pump per physician order.
If an altered state of consciousness or appropriateness is noted, the patient's blood sugar level is checked and:
if the patient is hypoglycemic, treatment is given per the Hypoglycemia Protocol policy, as appropriate, and the physician is notified of the patient's condition; if the patient is not hypoglycemic, the physician is notified of the patient's condition; if the physician orders that the insulin be suspended the RN calls the telephone number on the back of the patient's pump for instructions to suspend the infusion.
A physician order for alternative insulin therapy is obtained if the CSII pump is to be discontinued.
The RN obtains the patient's consent for the Continuous Subcutaneous Insulin Infusion Pump Therapy Patient Agreement (Appendix 2) on admission to the hospital. The physician is notified if the agreement is not signed by the patient.
The patient uses his/her own non-medication supplies for the CSII pump. Insulin is obtained from the Pharmacy for refill of the infusion pump.
On admission, the physician verifies the type of insulin in the patient's insulin pump. The patient may continue with his/her own insulin prefilled in the insulin pump until the pump requires a refill. For refilling the infusion pump, insulin is obtained from the pharmacy.
An Insulin Pump Basal/Bolus-Blood Glucose Record is placed at the patient's bedside. Basal and bolus rate doses are recorded by the patient/family and the results of blood glucose testing are taken by the RN. A target glucose range is listed on the glucose record as ordered by the endocrinologist or diabetic nurse educator.
A consult for the diabetes educator is initiated on admission to the hospital for patients who are receiving insulin via a CSII pump. The diabetic educator:
evaluates the patient's knowledge in the use of the insulin pump; downloads the insulin pump record (when possible) and places it in the patient's chart; assists nursing staff with documentation forms, evaluation, and care of the patient with an insulin pump; assesses the patient's home blood glucose monitor, downloads the report (when possible), and places the report in the patient's chart; orders a nutrition consult to initiate/reinforce carbohydrate counting skills. 
The Hypoglycemia Protocol for Known Diabetic Patients policy is followed if the patient experiences hypoglycemic events, and the physician is notified of the event.
If the patient requires a bolus dose to cover an elevated blood sugar episode and requires assistance from a family member to operate the pump and the family member does not respond to a page within 5 minutes, the RN gives a bolus dose of subcutaneous insulin to cover the elevated blood sugar episode, according to the physician order.
The patient changes the infusion set and reservoir every three (3) days with RN observation. More frequent changes are made if: the site is red, swollen, or warm to the touch; bleeding is noted at the site; discomfort is felt at the site; a "no delivery" alarm occurs without a tubing problem; two consecutive blood glucose readings are greater than 240 mg/dl If the patient is visually impaired, a sighted family member participates in all aspects of care related to CSII pump therapy.
The CSII pump must be removed prior to any radiological procedure that uses electromagnetic fields, such as MRI, CT scan, and/or X-rays. The pump is kept outside the room during any of these procedures. A physician order for an alternative dose of fast acting insulin is obtained prior to discontinuing the use of the pump. 
Documentation
Document that the CSII pump is present and infusing on admission, include the brand of the insulin pump, the type/name of insulin, and the basal rate. Document the initial assessment of the patient's ability to perform self-care. Document the patient's signature of the agreement. Document the assessment of site of injection of the needle, the patient's level of consciousness, orientation to person, place and time, the patient's risk for suicide and patient/family participation in self-care as performed. Document the basal rate of insulin, bolus doses, and blood glucose readings.
Additional Information
Do not remove the insulin reservoir/syringe from the pump while the infusion set is still attached to the patient.
During times of stress or infection, the patient often has increased insulin needs.
Blood glucose measurements used to determine bolus adjustments must be current. It is much safer to use values obtained from the point of care information available on the nursing unit rather than waiting for serum laboratory values to return. Any insulin dose given must be based on a reading obtained from the blood glucose monitor, due to its daily quality control and the connection of its information to the laboratory. 
DRAFT
Appendix 2 Continuous Subcutaneous Insulin Infusion Pump Therapy Patient Agreement
For your safety and optimal medical care during this hospitalization, we request that you agree to the following recommendations. If you feel that you cannot agree to these recommendations, we would like to treat your diabetes with insulin injections and request that you discontinue the use of your insulin pump.
During my hospital stay, I will agree to:
Show the nurse the bolus dose I am giving with each blood sugar, as needed.
Show the nurse my basal rate. Changes in any of my basal rates will only be made with a doctor's order.
Change the infusion set every 48-72 hours or as needed for: Skin problems, or Two blood glucose readings greater than 300 mg/dl in a row.
Provide my own non-medication insulin pump supplies.
Show and report the total daily dose of insulin.
Report signs of low blood sugar to the nurse.
Report any pump problems.
Ask questions that I may have about the use of the pump or doctor's orders.
If I cannot manage the pump myself, I may have a family member assist me and the medical staff with the operation of the insulin infusion pump on the condition that they must remain in the hospital during my entire stay. If the family member cannot remain in the hospital, the insulin infusion pump will need to be disconnected. 
